Sec matthew panuwat
Web24 Jan 2024 · The SEC sued Matthew Panuwat, a former senior director of business development at Medivation, an oncology-focused biopharmaceutical company, alleging … WebPanuwat Case According to the complaint, Matthew Panuwat, a former executive at Medivation, Inc., allegedly used his knowledge that Medivation was going to be acquired by a major biotechnology company at a "significant premium" to its stock price, to make more than $100,000 by trading in a competing biopharmaceutical company's stock.
Sec matthew panuwat
Did you know?
Web27 Jan 2024 · Panuwat, filed last year, the SEC alleged that Panuwat engaged in insider trading by purchasing those options. The case is the SEC’s first attempt to enforce its … Web25 Jan 2024 · 1 The SEC alleged that Matthew Panuwat, a biopharmaceutical executive, learned that his employer, Medivation, was due to announce an acquisition by Pfizer and, based on that information, immediately bought call options in a third pharmaceutical company, in the same market as Medivation. The court rejected Panuwat's arguments …
Web25 Apr 2024 · By an order issued on January 14, 2024, the United States District Court, Northern District of California allowed the Securities Exchange Commission (“SEC”) to … Web2 Feb 2024 · In Panuwat, the SEC alleged that Matthew Panuwat was a senior director at Medivation, Inc. — a "mid-cap, oncology-focused biopharmaceutical company." Panuwat's job responsibilities...
WebAccording to the SEC's complaint, just days before the announcement that Pfizer would acquire Medivation at a significant premium, Matthew Panuwat, the then-head of business development at Medivation, purchased "out-of-the-money, short-term stock options" in … Web25 Aug 2024 · Panuwat, who was the then-head of business development at Medivation, was closely engaged in internal discussions in the lead-up to Medivation’s acquisition by a large pharmaceutical company, including presentations from and other discussions with Medivation’s investment bankers.
Web26 Aug 2024 · Matthew Panuwat August 26, 2024 Share On August 17, 2024, the U.S. Securities and Exchange Commission (SEC) filed a litigated complaint against a former …
Web18 Aug 2024 · Panuwat made $107,000 on the short-term Incyte options trades, the SEC said. The case appears to be a rare instance of the SEC alleging insider trades in a … british \u0026 irish hypertension societyWebTHE SEC'S NOVEL THEORY The first test of the Securities and Exchange Commission's ("SEC") shadow trading theory in federal court has resulted in a win for the agency. On … capital house student accommodationWeb12 Jan 2024 · SEC v. Matthew Panuwat. Matthew Panuwat was a business development executive at Medivation, a mid-cap oncology-focused biopharmaceutical company. In … capital hot tubs mdWeb23 Feb 2024 · According to the SEC’s complaint, Matthew Panuwat was the senior director of business development at a mid-sized biopharmaceutical company. Panuwat allegedly … british typing keyboardWeb3 Feb 2024 · According to the SEC’s complaint, Matthew Panuwat was the senior director of business development at a mid-sized biopharmaceutical company. Panuwat allegedly … capital housing dc reviewsWeb25 Jan 2024 · [1] The SEC alleged that Matthew Panuwat, a biopharmaceutical executive, learned that his employer, Medivation, was due to announce an acquisition by Pfizer and, based on that information, immediately bought call options in a third pharmaceutical company, in the same market as Medivation. The court rejected Panuwat’s arguments … capital h shareholderWeb8 Mar 2024 · Panuwat, the SEC alleges that Matthew Panuwat, a former executive at Medivation Inc., an oncology biopharmaceutical company, learned that his company was to be acquired by Pfizer through an email … british u-class submarine